{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:10:01Z","timestamp":1792815001261,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010008","name":"Postdoctoral Science Foundation of Guangxi Province of China","doi-asserted-by":"publisher","award":["No:2019M660127"],"award-info":[{"award-number":["No:2019M660127"]}],"id":[{"id":"10.13039\/501100010008","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctoral Science Program Foundation of Jiangsu Province, China","award":["No:2019Z146"],"award-info":[{"award-number":["No:2019Z146"]}]},{"name":"the 2024 Provincial Basic Research Special Fund (Natural Science Foundation) General Project: The Role and Mechanism of Abnormal Arginine Metabolism in the Progression of Peripheral T-cell Lymphoma","award":["BK20241837"],"award-info":[{"award-number":["BK20241837"]}]},{"name":"Jiangsu Provincial Research Hospital Project","award":["YJXYY202204-XKB17"],"award-info":[{"award-number":["YJXYY202204-XKB17"]}]},{"name":"the Science and Technology Project of Nantong City","award":["MS22022111"],"award-info":[{"award-number":["MS22022111"]}]},{"name":"Project of the 14th Five Year Plan for Strengthening Science, Education, and Health of Nantong City, Cancer Clinical Medical Center","award":["NTYXZX18"],"award-info":[{"award-number":["NTYXZX18"]}]},{"name":"Jiangsu Province Capability Improvement Project through Science, Technology and Education","award":["ZDXK202234"],"award-info":[{"award-number":["ZDXK202234"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bruton tyrosine kinase (BTK), a key component of B-cell receptor signaling, is crucial for the development of B-cell malignancies. Covalent BTK inhibitors (cBTKis), such as ibrutinib, have demonstrated remarkable efficacy, but their curative potential is limited by acquired resistance. Next-generation BTK inhibitors, including non-covalent BTK inhibitors and BTK Proteolysis-targeting chimeras, offer new options for patients who have developed resistance to cBTKis. Some of these inhibitors have shown favorable efficacy and safety profiles, leading to Food and Drug Administration approval. This review summarizes the current landscape of BTK inhibitors, focusing on the evolution from cBTKis to next-generation inhibitors in terms of clinical efficacy and challenges, such as resistance mechanisms and off-target effects. We conclude with an outlook on future research and clinical applications.<\/jats:p>","DOI":"10.1007\/s00277-025-06515-7","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T03:21:14Z","timestamp":1753672874000},"page":"3929-3941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges"],"prefix":"10.1007","volume":"104","author":[{"given":"Yao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"8","key":"6515_CR1","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.mayocp.2015.04.025","volume":"90","author":"SM Ansell","year":"2015","unstructured":"Ansell SM (2015) Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 90(8):1152\u20131163","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"6515_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 17(1):57","journal-title":"Mol Cancer"},{"issue":"2","key":"6515_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y et al (2021) Inhibitors targeting bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia 35(2):312\u2013332","journal-title":"Leukemia"},{"issue":"4","key":"6515_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14(4):219\u2013232","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"6515_CR5","first-page":"808","volume":"11","author":"S Small","year":"2013","unstructured":"Small S (2013) Ibrutinib approved for the treatment of mantle cell lymphoma. Clin Adv Hematol Oncology: H&O 11(12):808","journal-title":"Clin Adv Hematol Oncology: H&O"},{"key":"6515_CR6","unstructured":"Dangi-Garimella S (2014) FDA grants accelerated approval for ibrutinib for CLL.\u00a0Am J Manag Care\u00a020(5 Spec No.):E10\u2013E10"},{"issue":"Spec Feature","key":"6515_CR7","first-page":"89","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler LA (2016) Imbruvica (Ibrutinib): first drug approved for the treatment of patients with waldenstr\u00f6m\u2019s macroglobulinemia. Am Health Drug Benefits 9(Spec Feature):89\u201392","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"6515_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A, Dhillon S (2018) Acalabrutinib: first global approval. Drugs 78(1):139\u2013145","journal-title":"Drugs"},{"issue":"1","key":"6515_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY (2020) Zanubrutinib: first approval. Drugs 80(1):91\u201397","journal-title":"Drugs"},{"issue":"4","key":"6515_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Orelabrutinib: first approval. Drugs 81(4):503\u2013507","journal-title":"Drugs"},{"key":"6515_CR11","doi-asserted-by":"crossref","unstructured":"Ondrisova L, Seda V, Hlavac K et al (2024) FoxO1\/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. J Clin Invest 134(23):e173770","DOI":"10.1172\/JCI173770"},{"issue":"11","key":"6515_CR12","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1182\/bloodadvances.2019001319","volume":"4","author":"HY Estupi\u00f1\u00e1n","year":"2020","unstructured":"Estupi\u00f1\u00e1n HY, Bouderlique T, He C et al (2020) Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. Blood Adv 4(11):2439\u20132450","journal-title":"Blood Adv"},{"issue":"1","key":"6515_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","volume":"14","author":"D Gu","year":"2021","unstructured":"Gu D, Tang H, Wu J et al (2021) Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol 14(1):40","journal-title":"J Hematol Oncol"},{"issue":"13","key":"6515_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D et al (2017) BTK(C481S)-Mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncology: Official J Am Soc Clin Oncol 35(13):1437\u20131443","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"18","key":"6515_CR15","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","volume":"129","author":"L Xu","year":"2017","unstructured":"Xu L, Tsakmaklis N, Yang G et al (2017) Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia. Blood 129(18):2519\u20132525","journal-title":"Blood"},{"key":"6515_CR16","doi-asserted-by":"crossref","unstructured":"Chen J, Kinoshita T, Gururaja T et al (2018) The effect of Bruton\u2019s tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC). Eur J Haematol","DOI":"10.1111\/ejh.13148"},{"issue":"5","key":"6515_CR17","doi-asserted-by":"publisher","first-page":"C373","DOI":"10.1152\/ajpcell.00325.2015","volume":"310","author":"RA Rigg","year":"2016","unstructured":"Rigg RA, Aslan JE, Healy LD et al (2016) Oral administration of bruton\u2019s tyrosine kinase inhibitors impairs GPVI-mediated platelet function. Am J Physiol Cell Physiol 310(5):C373\u2013C380","journal-title":"Am J Physiol Cell Physiol"},{"issue":"9","key":"6515_CR18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P et al (2014) Cell-cycle reprogramming for PI3K Inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 4(9):1022\u20131035","journal-title":"Cancer Discov"},{"issue":"11","key":"6515_CR19","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","volume":"129","author":"IE Ahn","year":"2017","unstructured":"Ahn IE, Underbayev C, Albitar A et al (2017) Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129(11):1469\u20131479","journal-title":"Blood"},{"issue":"1","key":"6515_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","volume":"30","author":"D Telaraja","year":"2024","unstructured":"Telaraja D, Kasamon YL, Collazo JS et al (2024) FDA approval summary: Pirtobrutinib for relapsed or refractory mantle cell lymphoma. Clin cancer Research: Official J Am Association Cancer Res 30(1):17\u201322","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"3","key":"6515_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1021\/acs.biochem.9b00848","volume":"59","author":"X Sun","year":"2020","unstructured":"Sun X, Rao Y (2020) PROTACs as potential therapeutic agents for Cancer drug resistance. Biochemistry 59(3):240\u2013249","journal-title":"Biochemistry"},{"issue":"26","key":"6515_CR22","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","volume":"57","author":"AD Buhimschi","year":"2018","unstructured":"Buhimschi AD, Armstrong HA, Toure M et al (2018) Targeting the C481S Ibrutinib-Resistance mutation in bruton\u2019s tyrosine kinase using PROTAC-Mediated degradation. Biochemistry 57(26):3564\u20133575","journal-title":"Biochemistry"},{"issue":"3","key":"6515_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A (2018) Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer 18(3):148\u2013167","journal-title":"Nat Rev Cancer"},{"issue":"7277","key":"6515_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88\u201392","journal-title":"Nature"},{"issue":"10","key":"6515_CR25","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1182\/blood-2006-11-056648","volume":"109","author":"CI Mockridge","year":"2007","unstructured":"Mockridge CI, Potter KN, Wheatley I et al (2007) Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 109(10):4424\u20134431","journal-title":"Blood"},{"issue":"1","key":"6515_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","volume":"128","author":"NS Saba","year":"2016","unstructured":"Saba NS, Liu D, Herman SE et al (2016) Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma. Blood 128(1):82\u201392","journal-title":"Blood"},{"issue":"10","key":"6515_CR27","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1074\/jbc.M602690200","volume":"282","author":"CM Radcliffe","year":"2007","unstructured":"Radcliffe CM, Arnold JN, Suter DM et al (2007) Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem 282(10):7405\u20137415","journal-title":"J Biol Chem"},{"issue":"5","key":"6515_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1074-7613(00)80417-3","volume":"4","author":"H Park","year":"1996","unstructured":"Park H, Wahl MI, Afar DE et al (1996) Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 4(5):515\u2013525","journal-title":"Immunity"},{"issue":"1","key":"6515_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li SJ et al (2007) Discovery of selective irreversible inhibitors for bruton\u2019s tyrosine kinase. ChemMedChem 2(1):58\u201361","journal-title":"ChemMedChem"},{"issue":"3","key":"6515_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"25","key":"6515_CR31","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425\u20132437","journal-title":"N Engl J Med"},{"issue":"5","key":"6515_CR32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE et al (2019) Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381(5):432\u2013443","journal-title":"N Engl J Med"},{"issue":"3","key":"6515_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","volume":"35","author":"C Visco","year":"2021","unstructured":"Visco C, Di Rocco A, Evangelista A et al (2021) Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia 35(3):787\u2013795","journal-title":"Leukemia"},{"issue":"12","key":"6515_CR34","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, Byrd JC, Hillmen P et al (2019) Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 3(12):1799\u20131807","journal-title":"Blood Adv"},{"issue":"31","key":"6515_CR35","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P et al (2021) Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncology: Official J Am Soc Clin Oncol 39(31):3441\u20133452","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"5","key":"6515_CR36","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR et al (2023) Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncology: Official J Am Soc Clin Oncol 41(5):1035\u20131045","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"11","key":"6515_CR37","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ajh.27064","volume":"98","author":"L Deng","year":"2023","unstructured":"Deng L, Li Z, Zhang H et al (2023) Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. Am J Hematol 98(11):1742\u20131750","journal-title":"Am J Hematol"},{"issue":"4","key":"6515_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.26826","volume":"98","author":"W Xu","year":"2023","unstructured":"Xu W, Zhou K, Wang T et al (2023) Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. Am J Hematol 98(4):571\u2013579","journal-title":"Am J Hematol"},{"issue":"1","key":"6515_CR39","doi-asserted-by":"publisher","first-page":"vdae037","DOI":"10.1093\/noajnl\/vdae037","volume":"6","author":"H Yonezawa","year":"2024","unstructured":"Yonezawa H, Narita Y, Nagane M et al (2024) Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neuro-oncology Adv 6(1):vdae037","journal-title":"Neuro-oncology Adv"},{"issue":"2","key":"6515_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","volume":"131","author":"NL Bartlett","year":"2018","unstructured":"Bartlett NL, Costello BA, LaPlant BR et al (2018) Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 131(2):182\u2013190","journal-title":"Blood"},{"issue":"1","key":"6515_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G et al (2015) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1(1):80\u201387","journal-title":"JAMA Oncol"},{"issue":"24","key":"6515_CR42","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P et al (2014) Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 370(24):2352\u20132354","journal-title":"N Engl J Med"},{"issue":"24","key":"6515_CR43","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM et al (2014) Resistance mechanisms for the bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370(24):2286\u20132294","journal-title":"N Engl J Med"},{"issue":"11","key":"6515_CR44","doi-asserted-by":"publisher","first-page":"102555","DOI":"10.1016\/j.jbc.2022.102555","volume":"298","author":"H Yuan","year":"2022","unstructured":"Yuan H, Zhu Y, Cheng Y et al (2022) BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma. J Biol Chem 298(11):102555","journal-title":"J Biol Chem"},{"issue":"6","key":"6515_CR45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Pirtobrutinib: first approval. Drugs 83(6):547\u2013553","journal-title":"Drugs"},{"issue":"1","key":"6515_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR et al (2023) Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 389(1):33\u201344","journal-title":"N Engl J Med"},{"key":"6515_CR47","unstructured":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24\u201327 (2025) February https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2025. Accessed 28 Feb 2025"},{"issue":"1","key":"6515_CR48","first-page":"62","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS et al (2023) Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood 142(1):62\u201372","journal-title":"Blood"},{"issue":"736","key":"6515_CR49","doi-asserted-by":"publisher","first-page":"eabg5216","DOI":"10.1126\/scisignal.abg5216","volume":"15","author":"K Dhami","year":"2022","unstructured":"Dhami K, Chakraborty A, Gururaja TL et al (2022) Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK. Sci Signal 15(736):eabg5216","journal-title":"Sci Signal"},{"issue":"24","key":"6515_CR50","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL et al (2023) Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated Mantle-Cell lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol 41(24):3988\u20133997","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"Supplement 1","key":"6515_CR51","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2023-181627","volume":"142","author":"JB Cohen","year":"2023","unstructured":"Cohen JB, Shah NN, Jurczak W et al (2023) Pirtobrutinib in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including High-Risk subgroup analyses from the phase 1\/2 BRUIN study. Blood 142(Supplement 1):981\u2013986","journal-title":"Blood"},{"issue":"9","key":"6515_CR52","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem A, Utro F, Wang Q et al (2023) Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv 7(9):1929\u20131943","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"6515_CR53","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood-2023-185852","volume":"142","author":"JA Woyach","year":"2023","unstructured":"Woyach JA, Brown JR, Ghia P et al (2023) Pirtobrutinib in Post-cBTKi CLL\/SLL: ~30 months Follow-up and subgroup analysis with\/without prior BCL2i from the phase 1\/2 BRUIN study. Blood 142(Supplement 1):325\u2013330","journal-title":"Blood"},{"key":"6515_CR54","doi-asserted-by":"crossref","unstructured":"Roeker LE, Woyach JA, Cheah CY et al (2023) Fixed-Duration Pirtobrutinib Combined with Venetoclax\u2009\u00b1\u2009Rituximab in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study. ASH Ann Meet Expos Session 642","DOI":"10.1182\/blood-2023-181090"},{"key":"6515_CR55","doi-asserted-by":"publisher","first-page":"101163","DOI":"10.1016\/j.blre.2023.101163","volume":"64","author":"A Barrett","year":"2024","unstructured":"Barrett A, Appleby N, Dreau H et al (2024) Richter\u2019s transformation: transforming the clinical landscape. Blood Rev 64:101163","journal-title":"Blood Rev"},{"issue":"Supplement 1","key":"6515_CR56","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/blood-2023-181108","volume":"142","author":"WG Wierda","year":"2023","unstructured":"Wierda WG, Shah NN, Cheah CY et al (2023) Pirtobrutinib in Richter transformation: updated efficacy and safety results with 18-Month median survival Follow-up from the phase 1\/2 BRUIN study. Blood 142(Supplement 1):1737","journal-title":"Blood"},{"issue":"Supplement 1","key":"6515_CR57","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2022-159123","volume":"140","author":"ML Palomba","year":"2022","unstructured":"Palomba ML, Patel MR, Eyre TA et al (2022) Efficacy of pirtobrutinib, a highly selective, Non-Covalent (Reversible) BTK inhibitor in Relapsed \/ Refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study. Blood 140(Supplement 1):557\u2013560","journal-title":"Blood"},{"issue":"10","key":"6515_CR58","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","volume":"8","author":"SD Reiff","year":"2018","unstructured":"Reiff SD, Mantel R, Smith LL et al (2018) The BTK inhibitor ARQ 531 targets Ibrutinib-Resistant CLL and Richter transformation. Cancer Discov 8(10):1300\u20131315","journal-title":"Cancer Discov"},{"issue":"4","key":"6515_CR59","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1182\/blood-2011-03-340109","volume":"118","author":"S Bhalla","year":"2011","unstructured":"Bhalla S, Evens AM, Dai B et al (2011) The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood 118(4):1052\u20131061","journal-title":"Blood"},{"issue":"1","key":"6515_CR60","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","volume":"14","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Stephens DM, Flinn IW et al (2024) First-in-Human study of the reversible BTK inhibitor Nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-Cell Non-Hodgkin lymphoma. Cancer Discov 14(1):66\u201375","journal-title":"Cancer Discov"},{"key":"6515_CR61","unstructured":"Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and, Pipeline O (2024) https:\/\/www.merck.com\/news\/merck-announces-phase-3-trial-initiations-for-four-investigational-candidates-from-its-promising-hematology-and-oncology-pipeline\/.\u00a0Accessed 5 Jan 2024\u00a0"},{"issue":"Supplement1","key":"6515_CR62","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/blood-2019-130784","volume":"134","author":"SB Howell","year":"2019","unstructured":"Howell SB, Zhang H, Rice WG (2019) A phase 1 a\/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL\/SLL or Non-Hodgkin\u2019s lymphomas. Blood 134(Supplement1):5477","journal-title":"Blood"},{"issue":"6","key":"6515_CR63","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1182\/blood.2021011516","volume":"139","author":"BMC Jebaraj","year":"2022","unstructured":"Jebaraj BMC, M\u00fcller A, Dheenadayalan RP et al (2022) Evaluation of vecabrutinib as a model for noncovalent BTK\/ITK Inhibition for treatment of chronic lymphocytic leukemia. Blood 139(6):859\u2013875","journal-title":"Blood"},{"issue":"1","key":"6515_CR64","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3324\/haematol.2021.279158","volume":"107","author":"B Aslan","year":"2022","unstructured":"Aslan B, Hubner SE, Fox JA et al (2022) Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica 107(1):292\u2013297","journal-title":"Haematologica"},{"issue":"8","key":"6515_CR65","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC et al (2022) Mechanisms of resistance to noncovalent bruton\u2019s tyrosine kinase inhibitors. N Engl J Med 386(8):735\u2013743","journal-title":"N Engl J Med"},{"issue":"6682","key":"6515_CR66","doi-asserted-by":"publisher","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","volume":"383","author":"S Montoya","year":"2024","unstructured":"Montoya S, Bourcier J, Noviski M et al (2024) Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Sci (New York NY) 383(6682):eadi5798","journal-title":"Sci (New York NY)"},{"issue":"4","key":"6515_CR67","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","volume":"67","author":"DW Robbins","year":"2024","unstructured":"Robbins DW, Noviski MA, Tan YS et al (2024) Discovery and preclinical Pharmacology of NX-2127, an orally bioavailable degrader of bruton\u2019s tyrosine kinase with Immunomodulatory activity for the treatment of patients with B cell malignancies. J Med Chem 67(4):2321\u20132336","journal-title":"J Med Chem"},{"issue":"Supplement 1","key":"6515_CR68","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/blood-2022-164772","volume":"140","author":"AR Mato","year":"2022","unstructured":"Mato AR, Wierda WG, Ai WZ et al (2022) NX-2127-001, a First-in-Human trial of NX-2127, a bruton\u2019s tyrosine Kinase-Targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-Cell malignancies. Blood 140(Supplement 1):2329\u20132332","journal-title":"Blood"},{"key":"6515_CR69","unstructured":"Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton\u2019s Tyrosine Kinase (BTK) (2023) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting. https:\/\/ir.nurixtx.com\/news-releases\/news-release-details\/nurix-therapeutics-presents-positive-clinical-data-its-novel. Accessed 11 Dec 2023"},{"key":"6515_CR70","unstructured":"Mihalic J (2023) First Disclosure of NX-5948, an Oral Targeted Degrader of Bruton\u2019s Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies. https:\/\/www.nurixtx.com\/wp-content\/uploads\/2023\/08\/NX5948-First.Disclosure-ACS-2023-Final.pdf. Accessed 16 Aug 2023"},{"issue":"24","key":"6515_CR71","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1111\/bph.17332","volume":"181","author":"Y Wu","year":"2024","unstructured":"Wu Y, Meibohm B, Zhang T et al (2024) Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton\u2019s tyrosine kinase-targeted protein degrader BGB-16673. Br J Pharmacol 181(24):4973\u20134987","journal-title":"Br J Pharmacol"},{"key":"6515_CR72","unstructured":"Wang H, Hou X, Zhang W, Overcomes on-target resistance from btk inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models BGB-16673, A BTK Degrader,. (Online) ISSN: 2572\u20139241"},{"issue":"Supplement 1","key":"6515_CR73","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1182\/blood-2023-180109","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, Cheah CY, Parrondo R et al (2023) First results from a phase 1, First-in-Human study of the bruton\u2019s tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-Cell malignancies (BGB-16673-101). Blood 142(Supplement 1):4401","journal-title":"Blood"},{"issue":"8Supplement","key":"6515_CR74","doi-asserted-by":"publisher","first-page":"CT128","DOI":"10.1158\/1538-7445.AM2023-CT128","volume":"83","author":"JY Li","year":"2023","unstructured":"Li JY, Xu W, Yan P et al (2023) Abstract CT128: phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies. Cancer Res 83(8Supplement):CT128","journal-title":"Cancer Res"},{"issue":"7Supplement","key":"6515_CR75","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1158\/1538-7445.AM2023-3450","volume":"83","author":"X Liu","year":"2023","unstructured":"Liu X, Zhou Y, Wu Y et al (2023) Abstract 3450: discovery and preclinical study of novel BTK degrader HZ-Q1070. Cancer Res 83(7Supplement):3450","journal-title":"Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06515-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06515-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06515-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T09:02:12Z","timestamp":1757667732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06515-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6515"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06515-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}